Evidence map›Paper›PMID 40760465›Full record

ArticleTrials2025

RANK-ligand inhibition to combat sarcopenia with underlying osteoporosis: a study protocol for a randomized, double-blind, double-dummy, active-controlled trial.

Ronald Man Yeung Wong, Pui Yan Wong, Chaoran Liu, Ning Tang, Raymond Chung Wai Wan, Wing Hong Liu, Can Cui, Ning Zhang, Timothy Chi Yui Kwok, Sheung Wai Law and 1 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06643780 (RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06643780 phase4recruitingnot on this map

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: a Randomized, Double-blind, Double-dummy, Active-Controlled Trial

TypeinterventionalSponsorPrince of Wales Hospital, Shatin, Hong KongRan2024 to 2027Enrolled120ConditionsSarcopenia in ElderlyArmsDenosumab, Zolendronic Acid
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ronald Man Yeung WongDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China. ronald.wong@cuhk.edu.hk.ORCID http://orcid.org/0000-0001-5615-6627
Pui Yan WongDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Chaoran LiuDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Ning TangDepartment of Orthopaedics & Traumatology, Prince of Wales Hospital, Hong Kong SAR, China.
Raymond Chung Wai WanDepartment of Orthopaedics & Traumatology, Prince of Wales Hospital, Hong Kong SAR, China.
Wing Hong LiuDepartment of Orthopaedics & Traumatology, Prince of Wales Hospital, Hong Kong SAR, China.
Can CuiDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Ning ZhangDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Timothy Chi Yui KwokDepartment of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Sheung Wai LawDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wing Hoi CheungDepartment of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China.

Funding

Health and Medical Research Fund 10210316
6 · The paper itself

Abstract

backgroundSarcopenia is an age-related disease characterized by gradual loss of muscle strength and muscle mass. Osteosarcopenia is the presence of osteopenia/osteoporosis and sarcopenia, which poses an increased risk of falls and fractures. Currently, there is no Food and Drug Administration (FDA) approved drug for treating sarcopenia. Previous studies showed that nuclear factor-κB ligand (RANKL) inhibition could reduce muscle atrophy and could be a therapeutic target for treating sarcopenia. Denosumab is an anti-osteoporotic drug with RANKL inhibition. This study aims to investigate the effects of denosumab to treat sarcopenia in patients with underlying osteoporosis.

methodsThis study is a randomized, double-blind, double-dummy, active-controlled trial for investigating the efficacy of denosumab in treating sarcopenia in patients with osteosarcopenia. Participants aged 65 years or above with osteosarcopenia will be recruited. Participants will be randomized into the denosumab group or the zoledronic acid group and will be followed up for 1 year. The primary outcomes are muscle strength, muscle mass measured by dual-energy x-ray absorptiometry (DXA) scan, and physical performance. The secondary outcomes are the clinical outcomes, including fall rate, fracture rate and mortality. DISCUSSION: This study will study the potential therapeutical effects of denosumab (RANKL inhibitor) on osteosarcopenia, which will be crucial given the aging population and expected increase in disease numbers.

trial registrationClinicalTrials.gov, NCT06643780. Registered on 16 October 2024. (Retrospectively registered and no protocol changes were made since the recruitment was started for this study).

Indexed as

Bone Density Conservation AgentsDenosumabOsteoporosisRANK LigandSarcopeniaAbsorptiometry, PhotonAgedBone DensityDouble-Blind MethodFemaleHumansMaleMuscle, SkeletalMuscle StrengthRandomized Controlled Trials as TopicTreatment OutcomeBone Density Conservation AgentsDenosumabRANK LigandTNFSF11 protein, humanZoledronic AcidOsteoporosisRandomized controlled trialRANKL inhibitorSarcopenia

Identifiers

PMID40760465
PMCPMC12323245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.